Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015

PHILADELPHIA, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash...
October 19, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)

PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
September 30, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma

PHILADELPHIA, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announces that Arrowhead BID issued an analyst report on September 29, 2015,...
September 28, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations

PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
September 23, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...
September 21, 2015 09:26 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive of Improved Response to Ampligen

PHILADELPHIA, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announces the publication of an online peer reviewed research article of an analysis of clinical data on its...
September 17, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study

PHILADELPHIA, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the approval by the Board of Directors for a Patient...
September 15, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Disease Symptoms

PHILADELPHIA, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today the publication in the current issue of the peer reviewed Journal of Clinical and Cellular...
September 02, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10, 2015

PHILADELPHIA, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) today announced it will be featured as a presenting company at the 17th Annual Rodman & Renshaw Global...
August 31, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Photo Release -- Hemispherx Biopharma Fully Aligns Executive Bonus Programs to Accelerate Product Revenue Opportunities and Market Entry

NEW BRUNSWICK, N.J., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing and Research and Development (R&D)...